<i>GBP5</i> Serves as a Potential Marker to Predict a Favorable Response in Triple-Negative Breast Cancer Patients Receiving a Taxane-Based Chemotherapy
Pre-operative (neoadjuvant) or post-operative (adjuvant) taxane-based chemotherapy is still commonly used to treat patients with triple-negative breast cancer (TNBC). However, there are still no effective biomarkers used to predict the responsiveness and efficacy of taxane-based chemotherapy in TNBC...
Main Authors: | Shun-Wen Cheng, Po-Chih Chen, Tzong-Rong Ger, Hui-Wen Chiu, Yuan-Feng Lin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Journal of Personalized Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4426/11/3/197 |
Similar Items
-
GBP5 Repression Suppresses the Metastatic Potential and PD-L1 Expression in Triple-Negative Breast Cancer
by: Shun-Wen Cheng, et al.
Published: (2021-04-01) -
Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy
by: Meiying Li, et al.
Published: (2018-01-01) -
Ethanol Extract of Brucea javanica Seed Inhibit Triple-Negative Breast Cancer by Restraining Autophagy via PI3K/Akt/mTOR Pathway
by: Xiaohong Chen, et al.
Published: (2020-04-01) -
YAP manipulates proliferation via PTEN/AKT/mTOR-mediated autophagy in lung adenocarcinomas
by: Wei Xu, et al.
Published: (2021-01-01) -
Dopamine Receptor Subtypes Differentially Regulate Autophagy
by: Dongmei Wang, et al.
Published: (2018-05-01)